CC - Sinocare Announces $273 million Purchase Agreement of Nipro Diagnostics –
Chinese BGM maker Sinocare announced a definitive purchase agreement to acquire Nipro Diagnostics from Nipro Corporation for $273 million earlier this week. Florida-based Nipro is known for its inexpensive store-brand and Nipro-branded BGMs, test strips, and lancets. This is the second acquisition news for Sinocare this year: in May, as we understand it, the company unsuccessfully offered ~$1 billion to acquire Bayer Diabetes Care (Panasonic ultimately won with a bid of ~$1.2 billion in June). This deal is certainly a lot cheaper! According to Nipro Diagnostics CEO Scott Verner, this transaction represents the merging of one of the fastest growing BGM companies in the US with the fastest growing BGM company in China. The acquisition is expected to be complete within 90 days, and we wonder about the implications for the US and global BGM markets. Could Sinocare scale Nipro’s business and offer even less expensive strips? Current Nipro offerings on Amazon are ~$5-$10 for meters and ~$18 for 100 strips ($0.20 per strip), and their Walgreens store brand strips are roughly ~$0.50-$0.70 per strip. The company’s TRUEtest strips held ~15% market share in the Medicare mail order market as of September 2013 (outpaced only by LifeScan and Prodigy). The big question for all store brand meters, of course, is accuracy, and Nipro meters have demonstrated poor results. The Nipro SideKick BGM had a 21% MARD in MGH’s comparative meter study presented at GTCBio in April, the worse of 17 BGMs tested (Bayer’s Contour Next meter was the best at a 6% MARD). Nipro’s most recent line of BGMs – TRUE METRIX and TRUE METRIX PRO – received FDA 510(k) clearance in September 2014. The company said these BGMs exceeded the most recent 2013 ISO standards for SMBG accuracy; of course, real-world accuracy is the big unknown with all meters post-clearance.
-- by Ava Runge, Adam Brown, and Kelly Close